2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Dipeptidyl Peptidase
  5. DPP-1 Isoform

DPP-1

 

DPP-1 Related Products (5):

Cat. No. Product Name Effect Purity
  • HY-101056
    Brensocatib
    		Inhibitor 99.88%
    Brensocatib (AZD7986) is an oral dipeptidyl peptidase 1 (DPP1) inhibitor with pIC50s of 6.85, 7.6, 7.7, 7.8, and 7.8 in human, mouse, rat, dog and rabbit, respectively.
  • HY-120709
    Propyl-GSK-2793660 hydrochloride
    		Inhibitor 98.71%
    Propyl-GSK-2793660 hydrochloride (compound 1) is a irreversible and covalent DPP1 inhibitor. Propyl-GSK-2793660 hydrochloride can be used for the study of bronchiectasis.
  • HY-174380
    DPP-1-IN-1
    		Inhibitor
    DPP-1-IN-1 (Compound 14) is an orally active inhibitor of Cathepsin C (also known as Dipeptidyl peptidase I) with an IC50 of 5.31 nM. DPP-1-IN-1 can inhibit the activity of Cathepsin C downstream Neutrophil elastase in neutrophils. DPP-1-IN-1 can be used in the research of inflammatory diseases.
  • HY-167937
    Propyl-GSK-2793660
    		Inhibitor
    Propyl-GSK-2793660 (compound 1) is a irreversible and covalent DPP1 inhibitor. Propyl-GSK-2793660 can be used for the study of bronchiectasis.
  • HY-172242
    Verducatib
    		Inhibitor 98.94%
    Verducatib (BI 1291583) is an orally active inhibitor of cathepsin C (also known as DPP1). Verducatib restores the protease-inhibitor balance by inhibiting the activation of neutrophil serine proteases, thereby alleviating pulmonary inflammation and regulating infection responses. Verducatib significantly reduces the risk (including severe exacerbations) and frequency of acute exacerbations in bronchiectasis (BE). Verducatib also improves lung function and quality of life, and shortens the duration of antibiotic use. The overall incidence of adverse events of Verducatib is comparable to that of placebo, with only slightly more mild-to-moderate cutaneous adverse events observed in the high-dose group, demonstrating promising clinical application potential.